Global Lung Cancer Diagnostic Tests Market Insights, Forecast to 2028

Table Of Contents

1 Report Business Overview

1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Lung Cancer Diagnostic Tests Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Immunoassays 1.2.3 Flow Cytometry 1.2.4 Rapid Tests 1.2.5 Molecular Assays 1.2.6 Tissue Arrays 1.2.7 Circulating Tumor Cells 1.2.8 Pharmacodiagnostics 1.2.9 Biomarkers 1.2.10 Other Diagnostics Methods 1.3 Market by Application 1.3.1 Global Lung Cancer Diagnostic Tests Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Precision Medicine 1.3.3 Personalized Medicine 1.3.4 Cancer Monitoring 1.4 Study Objectives 1.5 Years Considered2 Global Growth Trends 2.1 Global Lung Cancer Diagnostic Tests Market Perspective (2017-2028) 2.2 Lung Cancer Diagnostic Tests Growth Trends by Region 2.2.1 Lung Cancer Diagnostic Tests Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Lung Cancer Diagnostic Tests Historic Market Size by Region (2017-2022) 2.2.3 Lung Cancer Diagnostic Tests Forecasted Market Size by Region (2023-2028) 2.3 Lung Cancer Diagnostic Tests Market Dynamics 2.3.1 Lung Cancer Diagnostic Tests Industry Trends 2.3.2 Lung Cancer Diagnostic Tests Market Drivers 2.3.3 Lung Cancer Diagnostic Tests Market Challenges 2.3.4 Lung Cancer Diagnostic Tests Market Restraints3 Competition Landscape by Key Players 3.1 Global Top Lung Cancer Diagnostic Tests Players by Revenue 3.1.1 Global Top Lung Cancer Diagnostic Tests Players by Revenue (2017-2022) 3.1.2 Global Lung Cancer Diagnostic Tests Revenue Market Share by Players (2017-2022) 3.2 Global Lung Cancer Diagnostic Tests Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Lung Cancer Diagnostic Tests Revenue 3.4 Global Lung Cancer Diagnostic Tests Market Concentration Ratio 3.4.1 Global Lung Cancer Diagnostic Tests Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Lung Cancer Diagnostic Tests Revenue in 2021 3.5 Lung Cancer Diagnostic Tests Key Players Head office and Area Served 3.6 Key Players Lung Cancer Diagnostic Tests Product Solution and Service 3.7 Date of Enter into Lung Cancer Diagnostic Tests Market 3.8 Mergers & Acquisitions, Expansion Plans4 Lung Cancer Diagnostic Tests Breakdown Data by Type 4.1 Global Lung Cancer Diagnostic Tests Historic Market Size by Type (2017-2022) 4.2 Global Lung Cancer Diagnostic Tests Forecasted Market Size by Type (2023-2028)5 Lung Cancer Diagnostic Tests Breakdown Data by Application 5.1 Global Lung Cancer Diagnostic Tests Historic Market Size by Application (2017-2022) 5.2 Global Lung Cancer Diagnostic Tests Forecasted Market Size by Application (2023-2028)6 North America 6.1 North America Lung Cancer Diagnostic Tests Market Size (2017-2028) 6.2 North America Lung Cancer Diagnostic Tests Market Size by Type 6.2.1 North America Lung Cancer Diagnostic Tests Market Size by Type (2017-2022) 6.2.2 North America Lung Cancer Diagnostic Tests Market Size by Type (2023-2028) 6.2.3 North America Lung Cancer Diagnostic Tests Market Share by Type (2017-2028) 6.3 North America Lung Cancer Diagnostic Tests Market Size by Application 6.3.1 North America Lung Cancer Diagnostic Tests Market Size by Application (2017-2022) 6.3.2 North America Lung Cancer Diagnostic Tests Market Size by Application (2023-2028) 6.3.3 North America Lung Cancer Diagnostic Tests Market Share by Application (2017-2028) 6.4 North America Lung Cancer Diagnostic Tests Market Size by Country 6.4.1 North America Lung Cancer Diagnostic Tests Market Size by Country (2017-2022) 6.4.2 North America Lung Cancer Diagnostic Tests Market Size by Country (2023-2028) 6.4.3 U.S. 6.4.4 Canada7 Europe 7.1 Europe Lung Cancer Diagnostic Tests Market Size (2017-2028) 7.2 Europe Lung Cancer Diagnostic Tests Market Size by Type 7.2.1 Europe Lung Cancer Diagnostic Tests Market Size by Type (2017-2022) 7.2.2 Europe Lung Cancer Diagnostic Tests Market Size by Type (2023-2028) 7.2.3 Europe Lung Cancer Diagnostic Tests Market Share by Type (2017-2028) 7.3 Europe Lung Cancer Diagnostic Tests Market Size by Application 7.3.1 Europe Lung Cancer Diagnostic Tests Market Size by Application (2017-2022) 7.3.2 Europe Lung Cancer Diagnostic Tests Market Size by Application (2023-2028) 7.3.3 Europe Lung Cancer Diagnostic Tests Market Share by Application (2017-2028) 7.4 Europe Lung Cancer Diagnostic Tests Market Size by Country 7.4.1 Europe Lung Cancer Diagnostic Tests Market Size by Country (2017-2022) 7.4.2 Europe Lung Cancer Diagnostic Tests Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries8 Asia-Pacific 8.1 Asia-Pacific Lung Cancer Diagnostic Tests Market Size (2017-2028) 8.2 Asia-Pacific Lung Cancer Diagnostic Tests Market Size by Type 8.2.1 Asia-Pacific Lung Cancer Diagnostic Tests Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Lung Cancer Diagnostic Tests Market Size by Type (2023-2028) 8.2.3 Asia-Pacific Lung Cancer Diagnostic Tests Market Share by Type (2017-2028) 8.3 Asia-Pacific Lung Cancer Diagnostic Tests Market Size by Application 8.3.1 Asia-Pacific Lung Cancer Diagnostic Tests Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Lung Cancer Diagnostic Tests Market Size by Application (2023-2028) 8.3.3 Asia-Pacific Lung Cancer Diagnostic Tests Market Share by Application (2017-2028) 8.4 Asia-Pacific Lung Cancer Diagnostic Tests Market Size by Region 8.4.1 Asia-Pacific Lung Cancer Diagnostic Tests Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Lung Cancer Diagnostic Tests Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Lung Cancer Diagnostic Tests Market Size (2017-2028) 9.2 Latin America Lung Cancer Diagnostic Tests Market Size by Type 9.2.1 Latin America Lung Cancer Diagnostic Tests Market Size by Type (2017-2022) 9.2.2 Latin America Lung Cancer Diagnostic Tests Market Size by Type (2023-2028) 9.2.3 Latin America Lung Cancer Diagnostic Tests Market Share by Type (2017-2028) 9.3 Latin America Lung Cancer Diagnostic Tests Market Size by Application 9.3.1 Latin America Lung Cancer Diagnostic Tests Market Size by Application (2017-2022) 9.3.2 Latin America Lung Cancer Diagnostic Tests Market Size by Application (2023-2028) 9.3.3 Latin America Lung Cancer Diagnostic Tests Market Share by Application (2017-2028) 9.4 Latin America Lung Cancer Diagnostic Tests Market Size by Country 9.4.1 Latin America Lung Cancer Diagnostic Tests Market Size by Country (2017-2022) 9.4.2 Latin America Lung Cancer Diagnostic Tests Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil10 Middle East & Africa 10.1 Middle East & Africa Lung Cancer Diagnostic Tests Market Size (2017-2028) 10.2 Middle East & Africa Lung Cancer Diagnostic Tests Market Size by Type 10.2.1 Middle East & Africa Lung Cancer Diagnostic Tests Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Lung Cancer Diagnostic Tests Market Size by Type (2023-2028) 10.2.3 Middle East & Africa Lung Cancer Diagnostic Tests Market Share by Type (2017-2028) 10.3 Middle East & Africa Lung Cancer Diagnostic Tests Market Size by Application 10.3.1 Middle East & Africa Lung Cancer Diagnostic Tests Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Lung Cancer Diagnostic Tests Market Size by Application (2023-2028) 10.3.3 Middle East & Africa Lung Cancer Diagnostic Tests Market Share by Application (2017-2028) 10.4 Middle East & Africa Lung Cancer Diagnostic Tests Market Size by Country 10.4.1 Middle East & Africa Lung Cancer Diagnostic Tests Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Lung Cancer Diagnostic Tests Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE11 Key Players Profiles 11.1 Advpharma Inc 11.1.1 Advpharma Inc Company Details 11.1.2 Advpharma Inc Business Overview 11.1.3 Advpharma Inc Lung Cancer Diagnostic Tests Introduction 11.1.4 Advpharma Inc Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.1.5 Advpharma Inc Recent Developments 11.2 AIT Austrian Institute of Technology GmbH 11.2.1 AIT Austrian Institute of Technology GmbH Company Details 11.2.2 AIT Austrian Institute of Technology GmbH Business Overview 11.2.3 AIT Austrian Institute of Technology GmbH Lung Cancer Diagnostic Tests Introduction 11.2.4 AIT Austrian Institute of Technology GmbH Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.2.5 AIT Austrian Institute of Technology GmbH Recent Developments 11.3 Courtagen Life Sciences Inc 11.3.1 Courtagen Life Sciences Inc Company Details 11.3.2 Courtagen Life Sciences Inc Business Overview 11.3.3 Courtagen Life Sciences Inc Lung Cancer Diagnostic Tests Introduction 11.3.4 Courtagen Life Sciences Inc Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.3.5 Courtagen Life Sciences Inc Recent Developments 11.4 DiagnoCure Inc. (Inactive) 11.4.1 DiagnoCure Inc. (Inactive) Company Details 11.4.2 DiagnoCure Inc. (Inactive) Business Overview 11.4.3 DiagnoCure Inc. (Inactive) Lung Cancer Diagnostic Tests Introduction 11.4.4 DiagnoCure Inc. (Inactive) Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.4.5 DiagnoCure Inc. (Inactive) Recent Developments 11.5 BioMark Diagnostics Inc. 11.5.1 BioMark Diagnostics Inc. Company Details 11.5.2 BioMark Diagnostics Inc. Business Overview 11.5.3 BioMark Diagnostics Inc. Lung Cancer Diagnostic Tests Introduction 11.5.4 BioMark Diagnostics Inc. Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.5.5 BioMark Diagnostics Inc. Recent Developments 11.6 BioMarker Strategies LLC 11.6.1 BioMarker Strategies LLC Company Details 11.6.2 BioMarker Strategies LLC Business Overview 11.6.3 BioMarker Strategies LLC Lung Cancer Diagnostic Tests Introduction 11.6.4 BioMarker Strategies LLC Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.6.5 BioMarker Strategies LLC Recent Developments 11.7 Emory University 11.7.1 Emory University Company Details 11.7.2 Emory University Business Overview 11.7.3 Emory University Lung Cancer Diagnostic Tests Introduction 11.7.4 Emory University Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.7.5 Emory University Recent Developments 11.8 Epigenomics AG 11.8.1 Epigenomics AG Company Details 11.8.2 Epigenomics AG Business Overview 11.8.3 Epigenomics AG Lung Cancer Diagnostic Tests Introduction 11.8.4 Epigenomics AG Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.8.5 Epigenomics AG Recent Developments 11.9 GlycoZym 11.9.1 GlycoZym Company Details 11.9.2 GlycoZym Business Overview 11.9.3 GlycoZym Lung Cancer Diagnostic Tests Introduction 11.9.4 GlycoZym Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.9.5 GlycoZym Recent Developments 11.10 HalioDx SAS 11.10.1 HalioDx SAS Company Details 11.10.2 HalioDx SAS Business Overview 11.10.3 HalioDx SAS Lung Cancer Diagnostic Tests Introduction 11.10.4 HalioDx SAS Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.10.5 HalioDx SAS Recent Developments 11.11 Louisville Bioscience, Inc. 11.11.1 Louisville Bioscience, Inc. Company Details 11.11.2 Louisville Bioscience, Inc. Business Overview 11.11.3 Louisville Bioscience, Inc. Lung Cancer Diagnostic Tests Introduction 11.11.4 Louisville Bioscience, Inc. Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.11.5 Louisville Bioscience, Inc. Recent Developments 11.12 Mayo Clinic US 11.12.1 Mayo Clinic US Company Details 11.12.2 Mayo Clinic US Business Overview 11.12.3 Mayo Clinic US Lung Cancer Diagnostic Tests Introduction 11.12.4 Mayo Clinic US Revenue in Lung Cancer Diagnostic Tests Business (2017-2022) 11.12.5 Mayo Clinic US Recent Developments12 Analyst's Viewpoints/Conclusions13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer